Table 1.
Demographic and clinical characteristics of the subjects included in the study.
| n | Gender (% male) | Age: Mean ± SD (range) | Peak of eos (Pre-Tx): Median (IQR) | Peak of eos (Post-Tx): Median (IQR) | Type of Tx (EoE)/Main cause for endoscopy (controls) | ||
|---|---|---|---|---|---|---|---|
| EoE patients | 30 | 90% | 27.7 ± 10.9 (16–45) | 72 (49–98) | 0 (0–3) | ||
| EoE patients by treatment | FED | 10 | 90% | 25.1 ± 11.4 (16–38) | 100 (80–158) | 3 (1–8) | 2FED: 50%; 4FED: 40%; 6FED: 10% |
| PPI | 10 | 80% | 30.3 ± 10.2 (17–45) | 56 (43–60) | 3 (0–6) | Omeprazole: 90%; Lansoprazole: 10% | |
| STC | 10 | 100% | 27.6 ± 11.6 (16–44) | 66 (40–108) | 0 (0–0) | Budesonide: 90%; Fluticasone: 10% | |
| Non-EoE controls | 10 | 50% | 35.8 ± 12.7 (16–53) | ND | – | Dyspepsia: 60%; Dysphagia: 20%; Iron deficiency: 40% | |
EoE: eosinophilic oesophagitis; eos: eosinophils; n: number of subjects; Tx: treatment; IQR: interquartile range; FED: food-elimination diet; PPI: proton pump inhibitors; STC: swallowed topical corticosteroids; ND: not determined (2 controls had no detectable eosinophils, 8 controls had no histological alterations in the oesophageal epithelium).